Last checked at 
(Alliance News) - Pure Tech Health PLC on Thursday said its affiliate Follica announced topline results from its optimisation study to treat hair loss in male androgenetic alopecia.
The study was designed to select the optimal treatment regimen using Follica's proprietary device in combination with a topical drug and successfully met its primary endpoint, PureTech said.
PureTech holds a near 80% stake in Follica.
The stock closed up 5.6% at 285.00 pence, among the best performers in the FTSE 250 on Thursday.
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
